Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction

Abstract Aims The DELIVER study demonstrates a significant improvement in cardiovascular death or hospitalization for heart failure among heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF).Cost‐utility of the adjunct use of dapaglif...

Full description

Bibliographic Details
Main Authors: Yi Tang, Haiqiang Sang
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:ESC Heart Failure
Subjects:
Dapagliflozin
Cost‐utility analysis
Heart failure with preserved or mildly reduced ejection fraction
China
Online Access:https://doi.org/10.1002/ehf2.14426

Internet

https://doi.org/10.1002/ehf2.14426

Similar Items